June: Key issues: Dose / freq; B cell aplasia; CAR design for persistence; role in therapy for ALL; CD19 escape freq (~5% observed) #AACR14
11:46am April 7th 2014 via Hootsuite
June: Six institutes developing many targets, 4 int'l institutes also for CART19, and several pharmas #AACR14
11:45am April 7th 2014 via Hootsuite
June: How to scale to 1000's? Automation of robotic and cell culture. Mag bead T-cell enrichment, cryopreserved, ongoing work #AACR14
11:43am April 7th 2014 via Hootsuite
June: Toxicities include B-cell aplasia, Tumor Lysis syndrome, Cytokine release syndrome #AACR14
11:42am April 7th 2014 via Hootsuite
June: Roadblocks - have solved targeting, expansion; however toxicity is being addressed #AACR14
11:40am April 7th 2014 via Hootsuite
June: 7/16 adults in complete remission for ALL. Listed 6 potential roles for CAR Tcells for ALL, including an 'allo-Stem Cell XP' #AACR14
11:38am April 7th 2014 via Hootsuite
June: CARs shown to still persist 6mo. Have tracked to cerebral-spinal fluid. Rationale for neuro-oncology. #AACR14
11:37am April 7th 2014 via Hootsuite
June: Grupp speaking Tues 10:30am in pediatric session. #AACR14
11:34am April 7th 2014 via Hootsuite
June: Shift to ALL, Leukemial is still #1 pediatric cancer mortality, new treatment needed. Using CART19, Grupp 2013 NEJM ref #AACR14
11:33am April 7th 2014 via Hootsuite
June: Using qPCR of peripheral CTL019 cell expansion, distinguishing responders (>6% mononuclear cells threshold) #AACR14
11:31am April 7th 2014 via Hootsuite
June: Sustained Ab delivery with a single infusion of engineered T-cells shown. Showed expansion, persistence of CAR19+ cells #AACR14
11:30am April 7th 2014 via Hootsuite
June: Showed responsiveness and figures from David Porter, UPenn 2013 NEJM paper: http://t.co/60NFZcOVU1 #AACR14
11:29am April 7th 2014 via Hootsuite
June: Context of CLL survival: autologous T-cells, frozen. NCT01029366 NEJM ref 2013 http://t.co/n3AAZjG2Ch #AACR14
11:27am April 7th 2014 via Hootsuite
June: Cells thus have ability to survive in a hostile environment; CAR signalling domains can reprogram T-cells. Started testing '10 #AACR14
11:26am April 7th 2014 via Hootsuite
June: Cells in hypoxia, differentially affects CAR T-cell survival. Uses a Seahorse assay to look at oxidation states #AACR14
11:25am April 7th 2014 via Hootsuite
June: CD19 expressed in most B-cell malignancies; 2nd gen iteration Ref: 2009 PNAS Carpenito et al http://t.co/q1NHo7gG9Z #AACR14
11:24am April 7th 2014 via Hootsuite
June: First CAR trial for HIV in 1991 PubMed reference http://t.co/pZ1MNJ6TDG 11y persistance at stable levels 0.5% Tcells. 'safe' #AACR14
11:23am April 7th 2014 via Hootsuite
June: 2 approaches for modified T-cells - eng TCR's (retargeted spec) or 'CAR" using chimeric protein / tumor binding domain #AACR14
11:21am April 7th 2014 via Hootsuite
Mon AM Plenary: Carl June, Abramson Cancer Ctr (UPenn). "Engineering T cells for cancer: CARs in the clinic" #AACR14
11:17am April 7th 2014 via Hootsuite
AM Plenary: Targeted Immunotherapy: Mobilizing the Immune System Against Cancer. Chair: Susan Topalian, Johns Hopkins Kimmel CCC #AACR14
11:13am April 7th 2014 via Hootsuite
.@MrStemCell 12D = 12 dimensional data (yes that is a lot to think about, let alone visualize) #AACR14
11:08am April 7th 2014 via Hootsuite in reply to
Pe'er:Q:AML has an admixture of some normal cells A:In 2D or 3D, a problem. But in 12D the higher dimensions easy to separate out #AACR14
10:53am April 7th 2014 via Hootsuite
Pe'er:Q:Stability of metal complex? A:Not all Abs work, imp. measurement. But 16M cells, tech development the metals are stable #AACR14
10:52am April 7th 2014 via Hootsuite
Pe'er:Q:What effect of preanalyt var's? A:Cells were frozen for a long time (years), didn't have control until they work up #AACR14
10:50am April 7th 2014 via Hootsuite
Pe'er: Able to narrow B-cell subtype to 6 markers (so can use flow to separate) and then validated VDJ by qPCR as fn of developmt #AACR14
10:42am April 7th 2014 via Hootsuite
RT @BioWorld: If we learned anything from genomics, it’s 'don’t just look under the lamppost' -- Lynda Chin at #AACR14
10:39am April 7th 2014 via Hootsuite
Pe'er: Their method for B-cells - 25 surface markers, 18 internal, 5 stimuli, 10 samples (Cell, in press) 20K-300K healthy B-cells #AACR14
Pe'er: Development is non-linear; very hard to develop robust method. They developed a graph based trajectory (in a 30 pg suppl.!) #AACR14
10:38am April 7th 2014 via Hootsuite
Pe'er: Put all cells in the continuum - look at each marker and how it behaves over development #AACR14
10:35am April 7th 2014 via Hootsuite
Pe'er: Another story - B-cell development chronology to learn; Cell in press (Amir, Davis, Pe'er et al) Gate cells by 4 stages #AACR14
10:34am April 7th 2014 via Hootsuite
Pe'er: Flip it around, classify by signalling behavior. Looking at predictors of survival from 18 different samples. #AACR14
10:31am April 7th 2014 via Hootsuite
Pe'er: Data on pAkt, pSTAT3: cp normal and tumor cells, how signalling disrupted. Healthy vs AML clustering signaling phenotype #AACR14
10:25am April 7th 2014 via Hootsuite
Pe'er: The distribution difference - tool called Aperture. A messy matrix - 224 perturbation responses, 487 subpopulations #AACR14
10:23am April 7th 2014 via Hootsuite
Pe'er: Work only on surface markers; 19 perturbations. But more than an ave & diff - dev another tool to take distribution into acct #AA
10:21am April 7th 2014 via Hootsuite
Pe'er: The Columbia page on the viSNE tool: http://t.co/JJ2NAVwiHQ Amir et al Nature Biotech 2012 paper http://t.co/CVBLicJHPV #AACR14
10:20am April 7th 2014 via Hootsuite
Pe'er: Now looking at heterogeneity in AML, and has a structure. Colored by marker expression - about to segregate by cell-type #AACR14
10:18am April 7th 2014 via Hootsuite
Pe'er: Developed tool GRAPHITE, called 'a Facebook for cells'. k-nn with shared neighbors, Shared network similarity #AACR14
10:14am April 7th 2014 via Hootsuite
Pe'er: Another complexity level - how to look at response if the cells are ablated in analysis? But how to cluster with many dim's? #AACR14
10:12am April 7th 2014 via Hootsuite
Pe'er: Now looking at an AML cohort of 28 (instead of a single sample). Perturbations, 15 fn markers, 16 surface markers, 16M cells #AACR14
10:11am April 7th 2014 via Hootsuite
Pe'er: ALL map - visuallized, 0.007% population detected via this method #AACR14
10:10am April 7th 2014 via Hootsuite
Pe'er: How to visualize 30 dimensions? first developed viSNE map, publ Nature Biotech 2013 Amir et al #AACR14
10:09am April 7th 2014 via Hootsuite
Pe'er: Using heavy-metal labelled Abs, 45 dimensions in milliions of single cells. 5y old technology. PubMed:http://t.co/9VxFIFroXY #AACR14
10:06am April 7th 2014 via Hootsuite
Meet the expert: Dana Pe'er, Columbia. "Understanding tumor heterogeneity using 40 markers at single cell resolution" #AACR14
10:04am April 7th 2014 via Hootsuite
ICYMI: Elana Simon at the American Association for Cancer Research | Next Generation Technologist http://t.co/HABLgQi2EN #AACR14
9:21am April 7th 2014 via Hootsuite
Philly Tech Week to Feature World’s Biggest Tetris Game | Philadelphia Magazine http://t.co/oM75WW83nh
8:22am April 7th 2014 via Hootsuite
RT @MarilynMann: Reading is different online than off, experts say http://t.co/CGHyRodbBs via @washingtonpost
4:20am April 7th 2014 via Hootsuite
RT @WSJpersonaltech: Hubble Madness Heads to Final Round http://t.co/jX7NlzNnCT
3:20am April 7th 2014 via Hootsuite
RT @raulpacheco: PHD Comics: Programming for Non-Programmers http://t.co/KNhbQr6zMV
2:20am April 7th 2014 via Hootsuite
Post Edited: Elana Simon at the American Association for Cancer Research http://t.co/tqhdLMD5w4
1:12am April 7th 2014 via Wordpress Yuzuki Tweet posts
New post: Elana Simon at the American Association for Cancer Research http://t.co/tqhdLMD5w4
1:06am April 7th 2014 via Wordpress Yuzuki Tweet posts
